Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Epilepsy · Headline outcomes only

No studies found 0 · 0%GRADE not reported 3 · 42.9%Very low 0 · 0%Low 0 · 0%Moderate 4 · 57.1%High 0 · 0%

> 50% reduction in depressive symptoms · people with epilepsy and depression

Paroxetine showed no clear difference in > 50% reduction in depressive symptoms compared with doxepin (moderate certainty).

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
RR 1.16 [0.88, 1.52]
1 study · 67 participants
Moderate

Depressive symptoms · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 67 participants
Moderate

Seizure frequency · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Treatment withdrawal · people with epilepsy and depression

Paroxetine showed no clear difference in withdrawals compared with doxepin (moderate certainty).

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
RR 0.15 [0.01, 2.74]
1 study · 67 participants
Moderate

Cognitive function · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Quality of life · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Adverse effects · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 67 participants
Moderate